Summary & Overview
CPT 0569U: Guardant Reveal™ ctDNA Methylation NGS Assay
CPT code 0569U designates Guardant Reveal™, a proprietary circulating tumor DNA (ctDNA) next‑generation sequencing (NGS) assay that profiles over 20,000 DNA regions for abnormal methylation patterns linked to solid tumors and may report a tumor fraction. This PLA code is specific to a single manufacturer's test and reflects the growing role of blood‑based molecular diagnostics in oncology screening, surveillance, and personalized care. Nationally, such laboratory innovation affects payer coverage decisions, laboratory billing practices, and access to minimally invasive tumor detection tools.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of coverage and reimbursement benchmarks, payer policy considerations, clinical context for use of ctDNA methylation assays, and implications for billing and coding workflows. Readers will find a clear explanation of the test's clinical purpose and service setting, an overview of common modifiers used with laboratory services, and a summary of available payer approaches. Data not provided in the input are identified as unavailable. The content is intended for national stakeholders seeking a focused briefing on billing, clinical utility, and payer handling of CPT code 0569U.
Billing Code Overview
CPT code 0569U is a Proprietary Laboratory Analyses (PLA) code reported only for Guardant Reveal™ from Guardant Health Inc. The test uses next–generation sequencing (NGS) to examine more than 20,000 regions of DNA for abnormal methylation patterns associated with solid tumors. It analyzes circulating tumor DNA (ctDNA) in a blood sample to detect the presence or absence of tumor‑derived genetic material. When appropriate, results include a tumor fraction value.
Service type: Laboratory — circulating tumor DNA methylation NGS assay
Typical site of service: Outpatient laboratory or clinical laboratory setting using a blood specimen (phlebotomy)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of resected stage II colon adenocarcinoma presents for post-treatment surveillance. The treating oncologist orders a blood-based circulating tumor DNA (ctDNA) assay to evaluate for molecular residual disease and early recurrence. A peripheral blood draw is collected in the outpatient oncology clinic and sent to the manufacturer's laboratory. The Guardant Reveal™ test (0569U) uses next-generation sequencing to detect abnormal methylation patterns across >20,000 genomic regions and reports presence/absence of tumor-derived ctDNA and, when detectable, a tumor fraction value. Typical workflow steps: specimen collection (phlebotomy), specimen labeling and courier shipment under laboratory chain-of-custody, laboratory accessioning and sample processing, NGS-based methylation and ctDNA analysis, result interpretation by the performing laboratory, and transmission of a final report to the ordering oncologist. Typical sites of service include outpatient oncology clinics, ambulatory infusion centers, and independent phlebotomy or reference laboratory draw sites. Common clinical indications include surveillance after curative-intent therapy, evaluation for minimal residual disease, and adjunctive assessment for recurrence risk stratification.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the laboratory or performing provider documents and bills for markedly increased laboratory work or interpretive effort beyond typical requirements for the assay (rare for PLA tests). |